Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Abstract:

Objective To explore the preliminary efficacy of Disitamab Vedotin（RC48） as postoperative adjuvant therapy in patients with Her-2 positive locally advanced urothelial carcinoma.Methods The clinical data of 32 postoperative patients who received adjuvant therapy with RC48（RC48 group） and 104 postoperative patients who received conventional chemotherapy for locally advanced urothelial carcinoma（chemotherapy group） were retrospectively analyzed. The recurrence status of patients was followed up. The recurrence rate and adverse reaction rate of the two groups were compared.Results There were no significant differences in baseline data and preoperative/postoperative data between the two groups（P>0.05）. The recurrence rate（9.4%，1 case） of the RC48 group was significantly lower than that of the chemotherapy group（20.2%）（P=0.007）. The incidence of adverse reactions in the RC48 group（12.5%） was significantly lower than that in the chemotherapy group（20.2%）（P=0.022）.Conclusion Within 12 months of postoperative treatment，the recurrence rate and adverse reaction rate of patients in the RC48 group were lower than those in the conventional chemotherapy group，suggesting that RC48 has clinical significance in reducing the recurrence rate and delaying the progression of urothelial carcinoma in postoperative patients.